Metformin Actavis

Metformin, the active ingredient in Metformin Actavis, is a biguanide presented as a tablet for oral use. It decreases hepatic glucose production and improves peripheral insulin sensitivity, helping to control hyperglycemia in adults diagnosed with type 2 diabetes mellitus.

GNH USA supplies Metformin Actavis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality, regulatory compliance and reliable supply chain management for healthcare providers.

Metformin acts on glucose metabolism and is primarily used in the management of type 2 diabetes and related disorders.

Type 2 diabetes mellitus: improves glycaemic control by lowering fasting and post‑prandial glucose levels. Prediabetes (impaired fasting glucose): helps delay progression to overt diabetes when combined with lifestyle measures. Polycystic ovary syndrome (off‑label): may improve insulin resistance and menstrual regularity in affected women.

Metformin is generally well tolerated, but a range of adverse reactions has been reported.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, and diarrhoea. - Metallic taste: transient alteration in taste perception. - Weight loss: modest reduction in body weight. - Vitamin B12 deficiency: decreased absorption with long‑term use. - Lactic acidosis (rare): accumulation of lactate in susceptible individuals.

Serious or Rare Side Effects: - Severe hypoglycaemia: usually when combined with other glucose‑lowering agents. - Hepatic dysfunction: elevated liver enzymes in rare cases. - Skin reactions: rash or urticaria. - Acute pancreatitis: extremely uncommon but reported. - Allergic reactions: anaphylaxis or angioedema in very rare instances.

Metformin should be used with attention to patient‑specific factors and monitoring requirements. - Renal function: avoid or adjust dose in patients with impaired renal clearance. - Hepatic disease: use cautiously as liver dysfunction may increase lactate risk. - Cardiovascular status: monitor in patients with unstable heart failure. - Alcohol intake: limit consumption to reduce lactic acidosis risk. - Pregnancy and lactation: evaluate risk‑benefit; generally avoided unless clearly needed. - Store at ambient temperature: keep below 25 °C, retain in original container, protect from moisture and direct sunlight.

Metformin may interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Iodinated contrast agents: can precipitate acute renal failure, increasing lactic acidosis risk. - Cimetidine: may raise metformin plasma concentrations. - Certain antiretrovirals (e.g., didanosine): increase risk of lactic acidosis.

Moderate Interactions (Monitor Closely): - Diuretics: may affect renal clearance of metformin. - Beta‑blockers: can mask hypoglycaemia symptoms. - ACE inhibitors/ARBs: monitor renal function when combined. - Thyroid hormones: may require dose adjustment. - Oral contraceptives: may slightly increase metformin levels.